The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation

G.S. Scott; R.B. Kean; T. Mikheeva; M.J. Fabis; Jon Mabley; C. Szabo; D.C. Hooper

The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation

G.S. Scott
, R.B. Kean
, T. Mikheeva
, M.J. Fabis
, Jon Mabley
, C. Szabo
, D.C. Hooper

University of Brighton

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1053-1061
Number of pages	9
Journal	Journal of Pharmacology and Experimental Therapeutics
Volume	310
Publication status	Published - Sept 2004

Cite this

Scott, G. S., Kean, R. B., Mikheeva, T., Fabis, M. J., Mabley, J., Szabo, C., & Hooper, D. C. (2004). The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation. Journal of Pharmacology and Experimental Therapeutics, 310, 1053-1061.

Scott, G.S. ; Kean, R.B. ; Mikheeva, T. et al. / The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation. In: Journal of Pharmacology and Experimental Therapeutics. 2004 ; Vol. 310. pp. 1053-1061.

@article{9e6b5102ec8b45ca9d9c5c2e3ec3047f,

title = "The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation",

author = "G.S. Scott and R.B. Kean and T. Mikheeva and M.J. Fabis and Jon Mabley and C. Szabo and D.C. Hooper",

year = "2004",

month = sep,

language = "English",

volume = "310",

pages = "1053--1061",

journal = "Journal of Pharmacology and Experimental Therapeutics",

issn = "1521-0103",

}

Scott, GS, Kean, RB, Mikheeva, T, Fabis, MJ, Mabley, J, Szabo, C & Hooper, DC 2004, 'The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation', Journal of Pharmacology and Experimental Therapeutics, vol. 310, pp. 1053-1061.

The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation. / Scott, G.S.; Kean, R.B.; Mikheeva, T. et al.
In: Journal of Pharmacology and Experimental Therapeutics, Vol. 310, 09.2004, p. 1053-1061.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation

AU - Scott, G.S.

AU - Kean, R.B.

AU - Mikheeva, T.

AU - Fabis, M.J.

AU - Mabley, Jon

AU - Szabo, C.

AU - Hooper, D.C.

PY - 2004/9

Y1 - 2004/9

M3 - Article

SN - 1521-0103

VL - 310

SP - 1053

EP - 1061

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

ER -

Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley J, Szabo C et al. The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation. Journal of Pharmacology and Experimental Therapeutics. 2004 Sept;310:1053-1061.